Deutsche Bank AG Purchases 40,866 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Deutsche Bank AG increased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 17.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 274,134 shares of the medical equipment provider’s stock after acquiring an additional 40,866 shares during the period. Deutsche Bank AG’s holdings in Lantheus were worth $24,524,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in LNTH. T. Rowe Price Investment Management Inc. raised its stake in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock worth $135,025,000 after purchasing an additional 435,445 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Lantheus in the 4th quarter worth about $36,183,000. Swedbank AB raised its position in Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after buying an additional 385,000 shares during the last quarter. Keybank National Association OH purchased a new position in Lantheus in the 4th quarter worth about $27,526,000. Finally, Norges Bank bought a new position in Lantheus during the 4th quarter valued at about $26,189,000. 99.06% of the stock is owned by institutional investors.

Insider Transactions at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. The trade was a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. The trade was a 8.07% decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock worth $6,016,046 in the last three months. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a report on Thursday, May 8th. B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Finally, Truist Financial lowered their price target on Lantheus from $127.00 to $117.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $132.67.

Lantheus Stock Down 0.2%

NASDAQ LNTH opened at $78.81 on Thursday. The company has a 50-day moving average price of $98.18 and a 200-day moving average price of $93.72. Lantheus Holdings, Inc. has a 52 week low of $75.00 and a 52 week high of $126.89. The firm has a market capitalization of $5.40 billion, a P/E ratio of 13.11 and a beta of 0.23.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $372.76 million for the quarter, compared to analysts’ expectations of $377.37 million. During the same period in the prior year, the company posted $1.69 earnings per share. The firm’s quarterly revenue was up .8% on a year-over-year basis. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.